SCHEMBL10189308

SCHEMBL10189308

CC(=O)CNc1ccc(C)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
ALDH1A1 P00352 9/20 0.55
TDP1 Q9NUW8 2/20 0.55
LMNA P02545 2/20 0.55
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
MAPT P10636 6/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21518479 0.85 ALDH1A1 (0.58) POLBALDH1A1TDP1LMNAHDAC3
SCHEMBL4574261 0.83 USP2 (0.55) POLBALDH1A1TDP1LMNAHDAC3
SCHEMBL5113179 0.81 POLB (0.53) POLBALDH1A1TDP1LMNAHDAC3
SCHEMBL13359863 0.81 ALDH1A1 (0.57) POLBALDH1A1TDP1LMNAHDAC3
Hydrochloric Acid SCHEMBL5775146 0.80 POLB (0.51) POLBALDH1A1TDP1LMNAHDAC3
SCHEMBL10152983 0.80 POLB (0.51) POLBALDH1A1TDP1LMNAHDAC3
SCHEMBL31374324 0.80 POLB (0.56) POLBALDH1A1TDP1LMNAHDAC3
SCHEMBL13204733 0.79 ALDH1A1 (0.63) POLBALDH1A1TDP1LMNAHDAC3
SCHEMBL7824409 0.79 POLB (0.56) POLBALDH1A1TDP1LMNACA12
SCHEMBL9419326 0.78 MAPT (0.54) POLBALDH1A1TDP1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193168-B2 Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release REDPOINT BIO CORPORATION (US) 2012-06-05 US disclosed
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release REDPOINT BIO CORPORATION (US) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release GLP1R, GIPR, TRPM5 POLB 4849/4885ALDH1A1 4573/4885TDP1 4349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.